01Why You Need to Read "Beyond Regulation"
The first misreading a student of pharmaceutical advertising regulation often falls into is the assumption that "compliance with regulation eliminates risk." In practice, this is not true. Regulation is built reactively, in response to incidents that have already happened; current-day judgments always contain space that regulation never anticipated.
Consider concrete examples. At the time of the thalidomide disaster, pharmaceutical companies were fully complying with the laws and industry norms of the day. No deaths in animal testing, package inserts followed the standards then in force, advertising stayed within regulation. Even so, 10,000 fetuses were affected across 46 countries, and the subsequent regulatory reforms made teratogenicity testing — which had been outside regulation — mandatory. Regulatory compliance does not fully guarantee social responsibility at the moment of judgment.
The Diovan and Blopress incidents of the 1990s follow the same structure. Under the then-current interpretation of Pharmaceutical Act §66, the Tokyo District Court ruling was not guilty. Legally, the situation was clear. Yet the industry as a whole was asked by society "this was not okay", and the response was the birth of the Sales-Information-Provision Activity Guideline (HanteiG) and the Clinical Trials Act. See Ad Regulations 01 for details. The court's verdict and society's verdict are not the same thing.
What the field must ask is not only "is this in violation of regulation?" but also "what risk sits outside regulation?" This piece systematizes that question.
02The Four Layers of Risk — Legal, Industry Norm, Ethical, Social
The risk a pharmaceutical advertisement carries can be read in four layers. The further down, the more the layer escapes regulatory text.
Violations of Pharmaceutical Act §§66–68, the Advertising Appropriateness Standards, and HanteiG
Violations of explicitly codified law, public notices, and administrative guidance. Subject to PMDA / MHLW guidance, corrective orders, and criminal penalties. Judgment criteria are relatively clear; this is the layer that legal and compliance functions manage first.
Violations of the JPMA Code, the Creation Guidelines, and internal SOPs
Violations of industry self-regulation and internal craft. Not subject to legal punishment, but affecting industry reputation, client relationships, and internal personnel implications. Industry experience and internal culture are the core of the judgment.
Tension with medical ethics 4 principles and patient rights
Neither illegal nor in violation, but the question "does this serve the healthcare professional and the patient?" Read against the four principles of autonomy, non-maleficence, beneficence, and justice, does the expression, structure, or framing leave doubt?
The gaze of public opinion, social media, journalism, investors, and legislators
Falls under none of the above, but the question "can this withstand being placed in the public eye?" The possibility of social media backlash, journalistic feature treatment, investor / legislator / regulator interest. The least readable form of risk — capable of damaging the company and the industry independently of regulation.
Many organizations concentrate on the legal and industry-norm layers, and treat the ethical and social layers as "individual sensibility" not amenable to systematization. Yet most subsequent tragedies begin in the ethical and social layers. Thalidomide and Diovan were both compliant at the legal and industry-norm layers at the time. A suspecting eye for the ethical and social layers — this is the central theme of this piece.
03Doubting the "Fear of Misperception" Across Five Lenses
Most of the ethical and social risk concentrates around "the fear of misperception" — the possibility that the receiver interprets in a way the sender did not intend. HanteiG §3(2)(i) states "expressions inducing misperception are prohibited regardless of whether their delivery is active or passive," but the regulatory text alone does not reveal "how it can be misperceived." Five lenses for doubt:
Lens 1 — Reading beyond the literal
The possibility that the receiver reads "between the lines," from omissions, from the placement of emphasis — things not actually written. "A tendency for the effect to appear quickly" is, literally, a notation about a tendency; the patient reads "this will work quickly for me." Doubt starts from "what does the receiver read?", not from sender intent.
Lens 2 — Decontextualization
The possibility that a chart, citation, or quoted statement separates from its original context and circulates standalone. Through social media, copy-paste, screenshots — body text and footnotes vanish. Doubt asks "if extracted alone, does this still avoid being misread?"
Lens 3 — Visual balance bias
Efficacy in large font, bold color, top placement; side effects in small, faded color, bottom footnote. The text is present, but the visual weight is not equivalent. The U.S. 21 CFR 202.1 concept of Fair Balance, detailed in Overseas 01. Visual-balance bias rarely fails the regulatory test but stays vivid in the public eye.
Lens 4 — How the numbers are shown
"Twice the risk" is accurate as a relative risk, but if the absolute risk goes from 0.5% to 1%, the framing strongly induces misperception. Axis truncation in graphs, scale selection, omission of confidence intervals — same structure. The craft of "showing numbers" is itself a source of misperception.
Lens 5 — The boundary of implication and suggestion
Phrases like "almost," "can feel," "can be expected," "according to voices that evaluate it as" function as implications toward off-label territory. The sender makes no explicit claim, but the receiver reads it. Material Review Vol. 3 on "efficacy within the approved scope" addresses exactly this boundary.
04Whose Eye Is "the Public Eye"? — Seven Stakeholders
"The public eye" is an abstract phrase. Broken down concretely into whose eye, the seven types below give risk beyond regulation a three-dimensional form. Reading the same material from each of these vantages reveals discomfort that the legal and industry-norm layers did not surface.
① Patients and Families
Those carrying the disease, and their families. Reads it as "will this also save me?" They read with hope and disappointment, with household finances and treatment choices on their shoulders.
② Healthcare Professionals
Physicians, pharmacists, nurses bearing the responsibility for prescribing, reporting adverse events, and explaining to patients. Reads it as "can I trust this enough to prescribe?"
③ Media / Journalists
Industry reporters, specialist medical journals, general newspapers, television. Reads it as "is there wrongdoing here? Is this a story worth featuring?"
④ Social Media / General Public
X (Twitter), Threads, Reddit, comment boards. Reads it as "is there material for backlash here? An anger I'd want to share with someone close to me?"
⑤ Investors / Analysts
Institutional investors, sell-side analysts, ESG raters. Reads it as "do regulatory or reputational risks here move the stock?"
⑥ Legislators / Regulators
Health-policy legislators, PMDA, MHLW, Fair Trade Commission, Consumer Affairs Agency. Reads it as "is this a politicizable issue? A trigger for the next revision?"
⑦ Peer Companies / Industry Bodies
Competing pharmaceutical companies, the JPMA, industry KOLs. Reads it as "does this affect the industry overall? An expression that will be benchmarked?"
⑧ (Hidden eye) Your 5-year / 10-year future self
Looking back on the judgment of the time from the social common sense of the present. "How does the current me evaluate the decision of the time?" — the temporal public eye.
No material scores 100 with every stakeholder. But "if even one vantage marks it as fail, that is residual risk beyond regulation" — this is the discipline of reading the public eye.
05Cases — The Court's Verdict vs. Society's Verdict
Diovan — 2017 District Court Not Guilty
The 2017 Tokyo District Court ruling did not find the elements of Pharmaceutical Act §66 (exaggerated advertising "whether explicit or implicit") satisfied; the verdict was not guilty. the legal layer was clear. From the perspective of the industry and society, however, the structure of "a pharmaceutical company's employees organizationally participating in the academic side's data analysis" was itself a destruction of trust. measured against industry self-regulation, the conduct was strongly censured as a breach of industry self-regulation; measured against ethics, serious doubts persisted regarding research independence, conflicts of interest, and data integrity; measured against the public eye, the case is remembered as one that damaged the trust of the pharmaceutical industry as a whole. The response was the institution of HanteiG and the Clinical Trials Act. Even when you win in court, society's verdict effectively drives regulatory reform.
Thalidomide — Complete Compliance with the Then-Current Regulation
Chemie Grünenthal fully complied with the 1957-era animal-testing standards, package-insert standards, and advertising regulation. the legal and industry-norm layers — fully legal. The result was a tragedy in 46 countries. "Teratogenicity," a social-layer dimension regulation had never anticipated, drove the subsequent global regulatory revision. Details in Yakugai History 02.
Iressa (Japan, approved 2002) — Questioned on the timing of package-insert revisions
Iressa (gefitinib) was granted the world's first approval by Japan in 2002, and from immediately after its October launch deaths from interstitial pneumonia were reported. The package-insert recording was within the regulation and industry norms of the time, but society and the courts intensely questioned "the priority, the wording, and the speed of revision of the warnings." A typical case of compliant at the legal and industry-norm layers but challenged at the ethical and social layers — leading directly to the strengthening of post-marketing surveillance (PMS).
06How the Public Eye Has Changed in the Social Media and Video Era
The 2020s public eye differs qualitatively from the 20th century in three respects.
Shift 1 — The threshold for spread has dropped
Issues that once became social through journalistic coverage and industry feature pieces now spread with one screenshot and one post. "How does this look to the public eye?" must be read under the assumption of spread.
Shift 2 — Decontextualization is the default
Clip videos, partial quotation, summarizing AI — information stripped from its original context circulates further stripped. "Designed not to be misread when extracted alone" becomes a design-stage requirement.
Shift 3 — The temporal public eye
Past statements and materials are "evaluated by the sense of the present", made everyday by digital archiving. Expressions appropriate ten years ago come under question now — also a form of the public eye. Pharmaceutical advertising, as a medium that is searched and referenced over long timeframes, must incorporate the temporal public eye from the start.
07Systematizing the Suspecting Eye — Six Questions
The discussion above compresses into six questions usable in the field. Applied in order, at the points of material review, production oversight, or executive judgment, they capture ethical and social risk structurally.
"Does this expression leave room for the unwritten to be read?"
Between the literal meaning and what the receiver reads into it, is there a gap? If there is a gap, who fills it, and how?
"What does this material communicate when cut from its context and circulated alone?"
One chart, one quoted sentence, one screenshot — in standalone form, does it still avoid generating misperception?
"Of the seven stakeholders, is there one whose perspective marks a fail?"
Patient, healthcare professional, media, social media, investor, legislator, peer company, future self — if even one perspective registers discomfort, that is residual risk.
"If PMDA, MHLW, the Fair Trade Commission, or the Consumer Affairs Agency were to investigate, what would you say?"
On the assumption of a regulatory inquiry, can you write out the reasoning and decision-process? If you cannot, the judgment has not been documented.
"If this material were to go viral negatively, who in the company would announce what?"
From the communications lead's seat, can you assemble the anticipated Q&A? If you cannot, the field and executive intent statement is unprepared.
"If the you of five years from now saw the you of today's decision, what would they say?"
The temporal public eye. Not correctness at the moment, but verifiability over time as the perspective.
A material that can answer "clear" to all six questions has minimized risk across all four layers. A material that "trips on a word" at any one question — that is where the risk lives.
08Talking with the Executive Team — Quantifying Risk Beyond Regulation
The Suspecting Eye, kept as a field-level instinct, cannot be shared with executive leadership. To convey the ethical and social layers upward, three vocabularies work.
Vocabulary 1 — Probability of becoming a regulatory-revision trigger
"How structurally similar is this material to historic cases (Diovan, Thalidomide, Iressa)?" — graded on a three-level scale (low / medium / high). Even one "high" implies the possibility of driving industry-norm or statutory revision.
Vocabulary 2 — Estimating reputational damage
"If this material were to go viral negatively, the (a) effect on stock price (per industry historical norms), (b) effect on product revenue (suspension / revision costs), (c) effect on recruiting and personnel (years to rebuild trust)" — roughly estimated. The estimates matter less than the "habit of speaking in quantities", which creates a shared language with the executive team.
Vocabulary 3 — Long-horizon explainability
"Five years from now, ten years from now, do we have documents that can explain this decision to outside parties?" — judgment reasoning, decision process, norms consulted, audience considered, all documented and retained. If not retained, log that as risk of being unable to explain later, accounted at the current moment.
09In Closing — A Culture That Keeps Asking Beyond Regulation
This piece systematizes the "eye for reading regulation" that should be held before the concrete regulatory texts of Vols. 03–07 (HanteiG, HanteiG Q&A, the Advertising Appropriateness Standards, the JPMA Code, and the Creation Guidelines). Social risk, because regulation is always built reactively, is a domain that cannot be captured unless someone — in the present — keeps doubting.
To root the Suspecting Eye in an organization is not to add one checklist item to the regulatory-compliance review. It is to build a culture where, at every site of the work — field, review, executive — the question "this is lawful within regulation, but what does it look like when seen by the public eye?" keeps being asked. The culture does not depend on an individual's ethical sense. With this piece's structured tools — 4 layers, 7 stakeholders, 6 questions — as the organization's shared language, the seventy years of disasters and advertising incidents since thalidomide become avoidable. That is the last line of defense.
If Vols. 01 + 03–07 of this series provided the regulatory text as the field's weapon, this Vol. 02 — the Suspecting Eye — provides the eye that judges whether to draw the weapon. Holding both is what makes pharmaceutical advertising, as a craft, a practice that sustains social trust.